OR WAIT null SECS
© 2021 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
© 2021 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Paul K. Paik, MD, discusses the spectrum of targeted therapy in non-small cell lung cancer.
May 20th 2021
Paul K. Paik, MD, reviews the importance of biomarker testing and best practices in testing in patients with non-small cell lung cancer.
May 27th 2021
An expert in non-small cell lung cancer describes targetable gene alterations and how these impact treatment selection.
June 1st 2021
Paul K. Paik, MD, discusses currently available targeted therapies for patients with NSCLC.
A key opinion leader thoracic oncology reviews the clinical significance of MET exon 14 skipping in NSCLC as well as recent advances in MET-directed therapy.
An expert in non-small cell lung cancer discusses the key efficacy and safety findings from the VISION trial of tepotinib in patients with NSCLC and MET exon 14 skipping alterations.
Paul K. Paik, MD, discusses how the results of the VISION trial and the recent FDA approval of tepotinib will impact clinical practice.
Paul K. Paik, MD, considers the future of MET-directed therapies in non-small cell lung cancer.